An Exploratory Clinical Study of the Safety and Efficacy of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
Latest Information Update: 11 Jan 2026
At a glance
- Drugs RN 1701 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
Most Recent Events
- 11 Jan 2026 New trial record